Jian-Guo Zhou

Scopus Author ID Loop profile ORCID

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 21

Top Venues

Journal for immunotherapy of cancer

Technology in cancer research & treatment

Cancer control : journal of the Moffitt Cancer Center

Journal of periodontal research

Friedrich-Alexander-Universität Erlangen-Nürnberg

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Friedrich-Alexander-Universität Erlangen-Nürnberg Aug 12 2019

Germany

Ph.D. student :: Strahlenklinik

Affiliated Hospital of Zunyi Medical University Jun 01 2017

China

Doctor :: Department of Oncology

Publications

Ling Yang, Ying Cai, Yunjia Wang, Yue Huang, Chi Zhang, Hu Ma, Jian-Guo Zhou
Fibroblast Growth Factor 23 is a Potential Prognostic Biomarker in Uterine Sarcoma. Technology in cancer research & treatment 23 (2024)
Can Chen, Minjun Chen, Yuju Bai, Yajun Li, Jie Peng, Biao Yao, Jiangping Feng, Jian-Guo Zhou, Hu Ma
A Single-Arm Multi-Center Phase II Clinical Trial of Cadonilimab (anti-PD-1/CTLA-4) in Combination with or without Conventional Second-Line Treatment for Patients with Extensive Stage Small Cell Lung Cancer. Technology in cancer research & treatment 23 (2024)
Can Chen, Minjun Chen, Yuju Bai, Yajun Li, Jie Peng, Biao Yao, Jiangping Feng, Jian-Guo Zhou, Hu Ma
A Single-Arm Multi-Center Phase II Clinical Trial of Cadonilimab (anti-PD-1/CTLA-4) in Combination with or without Conventional Second-Line Treatment for Patients with Extensive Stage Small Cell Lung Cancer. Technology in cancer research & treatment 23 (2024)
Ling Yang, Ying Cai, Yunjia Wang, Yue Huang, Chi Zhang, Hu Ma, Jian-Guo Zhou
Fibroblast Growth Factor 23 is a Potential Prognostic Biomarker in Uterine Sarcoma. Technology in cancer research & treatment 23 (2024)
Shixiang Wang, Yi Xiong, Yihao Zhang, Haitao Wang, Minjun Chen, Jianfeng Li, Peng Luo, Yung-Hung Luo, Markus Hecht, Benjamin Frey, Udo S Gaipl, Xue-Jun Li, Qi Zhao, Hu Ma, Jian-Guo Zhou
TCCIA: a comprehensive resource for exploring CircRNA in cancer immunotherapy. Journal for immunotherapy of cancer 12 (1) (2024)
Shixiang Wang, Yi Xiong, Yihao Zhang, Haitao Wang, Minjun Chen, Jianfeng Li, Peng Luo, Yung-Hung Luo, Markus Hecht, Benjamin Frey, Udo S Gaipl, Xue-Jun Li, Qi Zhao, Hu Ma, Jian-Guo Zhou
TCCIA: a comprehensive resource for exploring CircRNA in cancer immunotherapy. Journal for immunotherapy of cancer 12 (1) (2024)
Shixiang Wang, Yi Xiong, Yihao Zhang, Haitao Wang, Minjun Chen, Jianfeng Li, Peng Luo, Yung-Hung Luo, Markus Hecht, Benjamin Frey, Udo S Gaipl, Xue-Jun Li, Qi Zhao, Hu Ma, Jian-Guo Zhou
TCCIA: a comprehensive resource for exploring CircRNA in cancer immunotherapy. Journal for immunotherapy of cancer 12 (1) (2024)
Can Chen, Minjun Chen, Yuju Bai, Yajun Li, Jie Peng, Biao Yao, Jiangping Feng, Jian-Guo Zhou, Hu Ma
A Single-Arm Multi-Center Phase II Clinical Trial of Cadonilimab (anti-PD-1/CTLA-4) in Combination with or without Conventional Second-Line Treatment for Patients with Extensive Stage Small Cell Lung Cancer. Technology in cancer research & treatment 23 (2024)
Can Chen, Minjun Chen, Yuju Bai, Yajun Li, Jie Peng, Biao Yao, Jiangping Feng, Jian-Guo Zhou, Hu Ma
A Single-Arm Multi-Center Phase II Clinical Trial of Cadonilimab (anti-PD-1/CTLA-4) in Combination with or without Conventional Second-Line Treatment for Patients with Extensive Stage Small Cell Lung Cancer. Technology in cancer research & treatment 23 (2024)
Shixiang Wang, Yi Xiong, Yihao Zhang, Haitao Wang, Minjun Chen, Jianfeng Li, Peng Luo, Yung-Hung Luo, Markus Hecht, Benjamin Frey, Udo S Gaipl, Xue-Jun Li, Qi Zhao, Hu Ma, Jian-Guo Zhou
TCCIA: a comprehensive resource for exploring CircRNA in cancer immunotherapy. Journal for immunotherapy of cancer 12 (1) (2024)
Shixiang Wang, Yi Xiong, Yihao Zhang, Haitao Wang, Minjun Chen, Jianfeng Li, Peng Luo, Yung-Hung Luo, Markus Hecht, Benjamin Frey, Udo S Gaipl, Xue-Jun Li, Qi Zhao, Hu Ma, Jian-Guo Zhou
TCCIA: a comprehensive resource for exploring CircRNA in cancer immunotherapy. Journal for immunotherapy of cancer 12 (1) (2024)
Jian-Guo Zhou, Yu Zeng, Haitao Wang, Su-Han Jin, Yun-Jia Wang, Sisi He, Benjamin Frey, Rainer Fietkau, Markus Hecht, Hu Ma, Wenchuan Zhang, Udo S Gaipl
Identification of an endogenous retroviral signature to predict anti-PD1 response in advanced clear cell renal cell carcinoma: an integrated analysis of three clinical trials. Therapeutic advances in medical oncology 14 (2022)
Yunhu Yu, Yu Zeng, Xiangping Xia, Jian-Guo Zhou, Fang Cao
Establishment and Validation of a Prognostic Immune Signature in Neuroblastoma. Cancer control : journal of the Moffitt Cancer Center 28 (2022)
Markus Hecht, Markus Eckstein, Sandra Rutzner, Jens von der Grün, Thomas Illmer, Gunther Klautke, Simon Laban, Matthias G Hautmann, Thomas B Brunner, Bálint Tamaskovics, Axel Hinke, Jian-Guo Zhou, Benjamin Frey, Anna-Jasmina Donaubauer, Ina Becker, Sabine Semrau, Arndt Hartmann, Panagiotis Balermpas, Wilfried Budach, Udo S Gaipl, Heinrich Iro, Antoniu-Oreste Gostian, Rainer Fietkau
Induction chemoimmunotherapy followed by CD8+ immune cell-based patient selection for chemotherapy-free radioimmunotherapy in locally advanced head and neck cancer. Journal for immunotherapy of cancer 10 (1) (2022)
Jian-Guo Zhou, Anna-Jasmina Donaubauer, Benjamin Frey, Ina Becker, Sandra Rutzner, Markus Eckstein, Roger Sun, Hu Ma, Philipp Schubert, Claudia Schweizer, Rainer Fietkau, Eric Deutsch, Udo S Gaipl, Markus Hecht
Prospective development and validation of a liquid immune profile-based signature (LIPS) to predict response of patients with recurrent/metastatic cancer to immune checkpoint inhibitors. Journal for immunotherapy of cancer 9 (2) (2022)
Jian-Guo Zhou, Bo Liang, Jian-Guo Liu, Su-Han Jin, Si-Si He, Benjamin Frey, Ning Gu, Sandra Rutzner, Markus Hecht, Hu Ma, Udo S Gaipl
Identification of 15 lncRNAs Signature for Predicting Survival Benefit of Advanced Melanoma Patients Treated with Anti-PD-1 Monotherapy. Cells 10 (5) (2021)
Jian-Guo Zhou, Lang Huang, Su-Han Jin, Cheng Xu, Benjamin Frey, Hu Ma, Udo S Gaipl
Olanzapine combined with 5-hydroxytryptamine type 3 receptor antagonist (5-HT3 RA) plus dexamethasone for prevention and treatment of chemotherapy-induced nausea and vomiting in high and moderate emetogenic chemotherapy: a systematic review and meta-analysis of randomised controlled trials. ESMO open 5 (1) (2021)
Anna-Jasmina Donaubauer, Jian-Guo Zhou, Oliver J Ott, Florian Putz, Rainer Fietkau, Ludwig Keilholz, Udo S Gaipl, Benjamin Frey, Thomas Weissmann
Low Dose Radiation Therapy, Particularly with 0.5 Gy, Improves Pain in Degenerative Joint Disease of the Fingers: Results of a Retrospective Analysis. International journal of molecular sciences 21 (16) (2020)
Su-Han Jin, Rui-Hao Zhou, Xiao-Yan Guan, Jian-Guo Zhou, Jian-Guo Liu
Identification of novel key lncRNAs involved in periodontitis by weighted gene co-expression network analysis. Journal of periodontal research 55 (1) (2019)
Zahra Fathi, Nicholas L Syn, Jian-Guo Zhou, Raheleh Roudi
Molecular epidemiology of lung cancer in Iran: implications for drug development and cancer prevention. Journal of human genetics 63 (7) (2018)
Jian-Guo Zhou, Nan-Jing Zhou, Qiong Zhang, Yao-Yao Feng, Hang Zhou
Apatinib for patients with advanced or recurrent cervical cancer: study protocol for an open-label randomized controlled trial. Trials 19 (1) (2018)

Jian-Guo Zhou.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Jian-Guo Zhou